{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:16Z","timestamp":1790753776273,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004871","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR 36"],"award-info":[{"award-number":["TRR 36"]}],"id":[{"id":"10.13039\/100004871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004871","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR179"],"award-info":[{"award-number":["TRR179"]}],"id":[{"id":"10.13039\/100004871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.coviro.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T08:17:02Z","timestamp":1525767422000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination"],"prefix":"10.1016","volume":"30","author":[{"given":"Claudia","family":"Dembek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roggendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.04.003_sbref0005","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.04.003_bib0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0015","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb Persp Med"},{"key":"10.1016\/j.coviro.2018.04.003_bib0020","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1128\/JVI.80.7.3532-3540.2006","article-title":"Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection","volume":"80","author":"Boettler","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri3169","article-title":"Living in the liver: hepatic infections","volume":"12","author":"Protzer","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tim.2015.01.013","article-title":"Towards an HIV-1 cure: measuring the latent reservoir","volume":"23","author":"Bruner","year":"2015","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1053\/j.gastro.2016.09.038","article-title":"\u201cTo Be or Not to Be\u201d: immune tolerance in chronic hepatitis B","volume":"151","author":"Protzer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0055","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1084\/jem.20150598","article-title":"High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival","volume":"213","author":"Utzschneider","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0060","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.04.003_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1751-7915.2011.00303.x","article-title":"Design of therapeutic vaccines: hepatitis B as an example","volume":"5","author":"Kutscher","year":"2012","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0075","first-page":"5","article-title":"The woodchuck, a nonprimate model for immunopathogenesis and therapeutic immunomodulation in chronic hepatitis B virus infection","author":"Roggendorf","year":"2015","journal-title":"Cold Spring Harb Persp Med"},{"key":"10.1016\/j.coviro.2018.04.003_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00430-014-0379-5","article-title":"Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck","volume":"204","author":"Kosinska","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0085","first-page":"817580","article-title":"Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck","volume":"2010","author":"Kosinska","year":"2010","journal-title":"Hepatitis Res Treat"},{"key":"10.1016\/j.coviro.2018.04.003_bib0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2015.12.060","article-title":"Protein-prime\/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice","volume":"34","author":"Backes","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.04.003_bib0095","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1128\/JVI.00506-12","article-title":"DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model","volume":"86","author":"Kosinska","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0100","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2014adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.04.003_bib0105","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.04.003_bib0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2014ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.04.003_bib0115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0120","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.vaccine.2017.03.049","article-title":"Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials","volume":"35","author":"Lobaina","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.04.003_bib0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00430-014-0381-y","article-title":"Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?","volume":"204","author":"Michel","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg\u2013HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0135","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A randomized controlled phase IIb trial of antigen\u2013antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.04.003_bib0140","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"6","author":"Cavenaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.04.003_bib0145","doi-asserted-by":"crossref","first-page":"935295","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0155","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0160","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"Honer Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.003_bib0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.coviro.2018.04.003_bib0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.coviro.2018.04.003_bib0175","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0180","article-title":"Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B","author":"Jeng","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0185","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0190","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis b patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0195","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.003_bib0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol Therapy Nucl Acids"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2018.04.003_bib0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.003_bib0220","doi-asserted-by":"crossref","first-page":"e0140909","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0225","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0230","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0235","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.04.003_bib0240","article-title":"Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo","author":"Quinet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0245","doi-asserted-by":"crossref","first-page":"e0179697","DOI":"10.1371\/journal.pone.0179697","article-title":"Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes","volume":"12","author":"Guillot","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.04.003_bib0250","doi-asserted-by":"crossref","first-page":"43838","DOI":"10.1038\/srep43838","article-title":"Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don\u2019t harbor immunostimulatory properties in primary isolated liver cells","volume":"7","author":"Real","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.04.003_bib0255","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2018.04.003_bib0260","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0140-6736(13)61998-4","article-title":"Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?","volume":"382","author":"Cohen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.04.003_sbref0265","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.003_bib0270","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA\/SCID mice with humanized livers and HBV infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.003_bib0275","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.coviro.2018.04.003_bib0280","first-page":"102","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.coviro.2018.04.003_bib0285","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","article-title":"Hepatitis B core protein as a therapeutic target","volume":"21","author":"Mak","year":"2017","journal-title":"Expert Opin Therapeutic Targets"},{"key":"10.1016\/j.coviro.2018.04.003_bib0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coviro.2017.03.019","article-title":"Novel viral and host targets to cure hepatitis B","volume":"24","author":"Ko","year":"2017","journal-title":"Curr Opin Virol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T19:44:16Z","timestamp":1565293456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718300373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":58,"alternative-id":["S1879625718300373"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.04.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}